Table 1.
Demographic, clinical, and laboratory characteristics of patients with GBS associated with COVID-19 and GBS non-associated with COVID-19
| GBS associated with COVID-19 group (n=13) | GBS non-associated with COVID-19 group (n=7) | ||
|---|---|---|---|
| % (n) | % (n) | p-value | |
| COVID-19 initial symptoms | Flu-like 30.7 (4) | - | |
| Cough 46.2 (6) | - | ||
| Dyspnoea 7.7 (1) | Dyspnoea 14.3 (1) | ||
| Diarrhoea 7.7 (1) | Diarrhoea 71.4 (5) | ||
| URTI 7.7 (1) | URTI 14.3 (1) | ||
| GBS initial symptoms | Assendan Weakness 61.5 (8) | Assendan Weakness 100 (7) | 0.067 |
| Facial diplegia and Assendan Weakness 30.8 (4) | |||
| Facial Diplegia 7.7 (1) | |||
| SARS-CoV-2 RT-PCR test results | Positive 69.2 (9) | ||
| Negative 30.8 (4) | |||
| Pulmonary involvement | Present 92.3 (12) | ||
| Absent 7.7 (1) | |||
| GBS subtype | AIDP 61.5 (8) | AIDP 71.4 (5) | 0.602 |
| AMSAN 30.8 (4) | AMSAN 28.6 (2) | ||
| AMAN 7.7 (1) | - | ||
| Treatment | IVIG 69.2 (9) | IVIG 85.7 (6) | 0.347 |
| PE+IVIG 7.7 (1) | PE+IVIG 14.3 (1) | ||
| PE 23.1 (3) | |||
| Response to treatment | None 23.1 (3) | _ | 0.094 |
| Partial 61.5 (8) | Partial 57.1 (4) | ||
| Complete 15.4 (2) | Complete 42.9 (3) | ||
| A need for mechanical ventilation | Absent 76.9 (10) | Absent 85.7 (6) | 0.648 |
| Present 23.1 (3) | Present 14.3 (1) | ||
| Comorbidities | No 38.5 (5) | No 71.4 (5) | 0.158 |
| DM 30.8 (4) | DM 14.3 (1) | ||
| DM+HT 23.1 (3) | _ | ||
| HT 7.7 (1) | HT 14.3 (1) | ||
AIDP: Acute Inflammatory Demyelinating Polyneuropathy; AMAN: Acute Motor Axonal Neuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; COVID-19: Coronavirus Disease-19; DM: Diabetes Mellitus; GBS: Guillain-Barré Syndrome; HT: Hypertension; IVIG: Intravenous Immunglobulin; PE: Plasma Exchange; SARS-CoV-2 RT-PCR: Severe Acute Respiratory Syndrome Coronavirus-2 Reverse Transcriptase Polymerase Chain Reaction; URTI: Upper Respiratory Tract Infection.